Discovering new antimicrobial agents

International Journal of Antimicrobial Agents

Volumn 37, Issue 1, 2011, Pages 2-9

  Moellering Jr , Robert C ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Antibacterial targets; Bacterial genomics; Drug discovery; Membrane active drugs; New antimicrobials

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BC 3208; BC 3781; BISPHOSPHONIC ACID DERIVATIVE; DALBAVANCIN; FIDAXOMICIN; FUSIDIC ACID; LACTAM DERIVATIVE; LINEZOLID; LYSOSTAPHIN; MODITHROMYCIN; NOVOBIOMYCIN; NOVOLACTAMYCIN; NXL 103; OMADACYCLINE; ORITAVANCIN; OXAZOLIDINONE DERIVATIVE; POLYPEPTIDE ANTIBIOTIC AGENT; PRISTINAMYCIN; RADEZOLID; RETAPAMULIN; RIFAMYCIN; STREPTOGRAMIN DERIVATIVE; TELAVANCIN; TELITHROMYCIN; TOREZOLID; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANCOMYCIN; VIC 200107;

ACUTE DISEASE; ANTIMICROBIAL ACTIVITY; BACTERIAL SKIN DISEASE; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BACTERICIDAL ACTIVITY; BACTERIOPHAGE; CATHETER INFECTION; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE INFECTION; COMMUNITY ACQUIRED PNEUMONIA; CONFERENCE PAPER; DENTAL CARIES; DRUG BIOAVAILABILITY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DRUG RESEARCH; DRUG SAFETY; HUMAN; LIVER TOXICITY; MUSCLE WEAKNESS; MYASTHENIA GRAVIS; NONHUMAN; OSTEOMYELITIS; PRIORITY JOURNAL; SKIN INFECTION; STAPHYLOCOCCUS INFECTION; VISUAL DISORDER;

ANTI-INFECTIVE AGENTS; DRUG DISCOVERY;

EID: 78650260056     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2010.08.018     Document Type: Conference Paper

References (62)

1. H.W. Boucher, G.H. Talbot, J.S. Bradley, J.E. Edwards, D. Gilbert, and L.B. Rice Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America Clin Infect Dis 48 2009 1 12
2. Infectious Diseases Society of America. The 10 × 20 initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020. Clin Infect Dis 2010;50:1081-3.
3. D.J. Payne, M.N. Gwynn, D.J. Holmes, and D.L. Pompliano Drugs for bad bugs: confronting the challenges of antibacterial discovery Nat Rev Drug Discov 6 2007 29 40
4. J.L. Fox The business of developing antibacterials Nat Biotechnol 24 2006 1521 1528
5. A.D. So, N. Gupta, and O. Cars Tackling antibiotic resistance BMJ 340 2010 c2071
6. Shifting goalposts in antibiotic approval. Lancet Infect Dis 2006;6:751.
7. U. Theuretzbacher Future antibiotics scenarios: is the tide starting to turn? Int J Antimicrob Agents 34 2009 15 20
8. J.F. Kokai-Kun, T. Chanturiya, and J.J. Mond Lysostaphin as a treatment for systemic Staphylococcus aureus infection in a mouse model J Antimicrob Chemother 60 2007 1051 1059
9. R. Novak, and D.M. Shlaes The pleuromutilin antibiotics: a new class for human use Curr Opin Investig Drugs 11 2010 182 191
10. G. Morales, J.J. Picazo, E. Baos, F.J. Candel, A. Arribi, and B. Peláez Resistance to linezolid is mediated by the cfr gene in the first report of an outbreak of linezolid-resistant Staphylococcus aureus Clin Infect Dis 50 2010 821 825
11. H. Brötz, and H.G. Sahl New insights into the mechanism of action of lantibiotics - diverse biological effects by binding to the same molecular target J Antimicrob Chemother 46 2000 1 6
12. T.J. Louie, J. Emery, W. Krulicki, B. Byrne, and M. Mah OPT-80 eliminates Clostridium difficile and is sparing of Bacteroides species during treatment of C. difficile infection Antimicrob Agents Chemother 53 2009 261 263
13. N. Silva, H. Radhouani, A. Gonalves, C. Araújo, J. Rodrigues, and G. Igrejas In vitro activity of ceftobiprole against Gram-positive and Gram-negative bacteria isolated from humans and animals J Antimicrob Chemother 65 2010 801 803
14. Y. Ge, D. Biek, G.H. Talbot, and D.F. Sahm In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States Antimicrob Agents Chemother 52 2008 3398 3407
15. C.C. Bulik, H. Christensen, and D.P. Nicolau In vitro potency of CXA-101, a novel cephalosporin, against Pseudomonas aeruginosa displaying various resistance phenotypes, including multidrug resistance Antimicrob Agents Chemother 54 2010 557 559
16. Bertrand D, Bertrand S, Neveu E, Fernandes P. Molecular characterization of off-target activities of telithromycin: a potential role of nicotinic acetylcholine receptors. Antimicrob Agents Chemother 2010 Sep 20 [Epub ahead of print].
17. L.D. Saravolatz, G.E. Stein, and L.B. Johnson Telavancin: a novel lipoglycopeptide Clin Infect Dis 49 2009 1908 1914
18. N.E. Allen, and T.I. Nicas Mechanism of action of oritavancin and related glycopeptide antibiotics FEMS Microbiol Rev 26 2003 511 532
19. M. Ge, Z. Chen, H.R. Onishi, J. Kohler, L.L. Silver, and R. Kerns Vancomycin derivatives that inhibit peptidoglycan biosynthesis without binding d-Ala-d-Ala Science 284 1999 507 511
20. C.S. Lunde, S.R. Hartouni, J.W. Janc, M. Mammen, P.P. Humphrey, and B.M. Benton Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor lipid II Antimicrob Agents Chemother 53 2009 3375 3383
21. S.S. Hedge, R. Skinner, S.R. Lewis, K.M. Krause, J. Blais, and B.M. Benton Activity of telavancin against heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) in vitro and in an in vivo mouse model of bacteraemia J Antimicrob Chemother 65 2010 725 728
22. M. Billeter, M.J. Zervos, A.Y. Chen, J.R. Dalovisio, and C. Kurukularatne Dalbavancin: a novel once-weekly lipoglycopeptide antibiotic Clin Infect Dis 46 2008 577 583
23. F.F. Arhin, D.C. Draghi, C.M. Pillar, T.R. Parr Jr., G. Moeck, and D.F. Sahm Comparative in vitro activity profile of oritavancin against recent Gram-positive clinical isolates Antimicrob Agents Chemother 53 2009 4762 4771
24. C.M. Rubino, S.A. Van Wart, S.M. Bhavnani, P.G. Ambrose, J.S. McCollam, and A. Forrest Oritavancin population pharmacokinetics in healthy subjects and patients with complicated skin and skin structure infections or bacteremia Antimicrob Agents Chemother 53 2009 4422 4428
25. L.S. Almer, J.B. Hoffrage, E.L. Keller, R.K. Flamm, and V.D. Shortridge In vitro and bactericidal activities of ABT-492, a novel fluoroquinolone, against Gram-positive and Gram-negative organisms Antimicrob Agents Chemother 48 2004 2771 2777
26. R. Schaadt, D. Sweeney, D. Shinabarger, and G. Zurenko In vitro activity of TR-700, the active ingredient of the antibacterial prodrug TR-701, a novel oxazolidinone antibacterial agent Antimicrob Agents Chemother 53 2009 3236 3239
27. M.G.P. Page, C. Dantier, and E. Desarbre In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant Gram-negative bacilli Antimicrob Agents Chemother 54 2010 2291 2302
28. N.A.C. Curtis, R.L. Eisenstadt, S.J. East, R.J. Cornford, L.A. Walker, and A.J. White Iron-regulated outer membrane proteins of Escherichia coli K-12 and mechanism of action of catechol-substituted cephalosporins Antimicrob Agents Chemother 32 1988 1879 1886
29. P. Silley, J.W. Griffiths, D. Monsey, and A.M. Harris Mode of action of GR69153, a novel catechol-substituted cephalosporin, and its interaction with the tonB-dependent iron transport system Antimicrob Agents Chemother 34 1990 1806 1808
30. R.C. Moellering Jr. Rationale for the use of antibiotic combinations Am J Med 75 1983 4 8
31. R.C. Moellering Jr. Can the third-generation cephalosporins eliminate the need for antimicrobial combinations? Am J Med 79 1985 104 109
32. O. Lomovskaya, M.S. Warren, A. Lee, J. Galazzo, R. Fronko, and M. Lee Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: novel agents for combination therapy Antimicrob Agents Chemother 45 2001 105 116
33. S.M. Drawz, and R.A. Bonomo Three decades of β-lactamase inhibitors Clin Microbiol Rev 23 2010 160 201
34. A. Bonnefoy, C. Dupuis-Hamelin, V. Steier, C. Delachaume, C. Seys, and T. Stachyra In vitro activity of AVE1330A, an innovative broad-spectrum non-β-lactam β-lactamase inhibitor J Antimicrob Chemother 54 2004 410 417
35. N.H. Georgopapadakou, and A. Bertasso Mechanisms of action of cephalosporin 3′-quinolone esters, carbamates, and tertiary amines in Escherichia coli Antimicrob Agents Chemother 37 1993 559 565
36. M.M. Butler, W.A. LeMarr, K.A. Foster, M.H. Barnes, D.J. Skow, and P.T. Lyden Antibacterial activity and mechanism of action of a novel anilinouracil-fluoroquinolone hybrid compound Antimicrob Agents Chemother 51 2007 119 127
37. J. He, D.K. Yarbrough, J. Kreth, M.H. Anderson, W. Shi, and R. Eckert Systematic approach to optimizing specifically targeted antimicrobial peptides against Streptococcus mutans Antimicrob Agents Chemother 54 2010 2143 2151
38. R.E.W. Hancock, and D.S. Chapple Peptide antibiotics Antimicrob Agents Chemother 43 1999 1317 1323
39. J. Garnacho-Montero, C. Ortiz-Leyba, F.J. Jiménez-Jiménez, A.E. Barrero-Almodóvar, J.L. García-Garmendia, and M. Bernabeu-WittelI Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP Clin Infect Dis 36 2003 1111 1118
40. O. Levy A neutrophil-derived anti-infective molecule: bactericidal/permeability-increasing protein Antimicrob Agents Chemother 44 2000 2925 2932
41. M. Levin, P.A. Quint, B. Goldstein, P. Barton, J.S. Bradley, and S.D. Shemie Recombinant bactericidal/permeability-increasing protein (rBPI21) as adjunctive treatment for children with severe meningococcal sepsis: a randomised trial. rBPI21 Meningococcal Sepsis Study Group Lancet 356 2000 961 967
42. N. Ooi, K. Miller, C. Randall, W. Rhys-Williams, W. Love, and I. Chopra XF-70 and XF-73, novel antibacterial agents active against slow-growing and non-dividing cultures of Staphylococcus aureus including biofilms J Antimicrob Chemother 65 2010 72 78
43. D. Liu, S.-W. Choi, B. Chen, R.J. Doerksen, D.J. Clements, and J.D. Winkler Nontoxic membrane-active antimicrobial arylamide oligomers Angew Chem Int Ed Engl 43 2004 1158 1162
44. Z. Jiang, B.J. Kullberg, H. van der Lee, A.I. Vasil, J.D. Hale, and C.T. Mant Effects of hydrophobicity on the antifungal activity of α-helical antimicrobial peptides Chem Biol Drug Des 72 2008 483 495
45. Y. Chen, M.T. Guarnieri, A.I. Vasil, M.L. Vasil, C.T. Mant, and R.S. Hodges Role of peptide hydrophobicity in the mechanism of action of α-helical antimicrobial peptides Antimicrob Agents Chemother 51 2007 1398 1406
46. N. Srinivas, P. Jetter, B.J. Ueberbacher, M. Werneburg, K. Zerbe, and J. Steinmann Peptidomimetic antibiotics target outer-membrane biogenesis in Pseudomonas aeruginosa Science 327 2010 1010 1013
47. J. Pannu, A. McCarthy, A. Martin, T. Hamouda, S. Ciotti, and A. Fothergill NB-002, a novel nanoemulsion with broad antifungal activity against dermatophytes, other filamentous fungi, and Candida albicans Antimicrob Agents Chemother 53 2009 3273 3279
48. J.J. LiPuma, S. Rathinavelu, B.K. Foster, J.C. Keoleian, P.E. Makidon, and L.M. Kalikin In vitro activities of a novel nanoemulsion against Burkholderia and other multidrug-resistant cystic fibrosis-associated bacterial species Antimicrob Agents Chemother 53 2009 249 255
49. D.L. Stevens, Y. Ma, D.B. Salmi, E. McIndoo, R.J. Wallace, and A.E. Bryant Impact of antibiotics on expression of virulence-associated exotoxin genes in methicillin-sensitive and methicillin-resistant Staphylococcus aureus J Infect Dis 195 2007 202 211
50. R.G. Finch, D.I. Pritchard, B.W. Bycroft, P. Williams, and G.S.A.B. Stewart Quorum sensing: a novel target for anti-infective therapy J Antimicrob Chemother 42 1998 569 571
51. J.F. Barrett, and J.A. Hoch Two-component signal transduction as a target for microbial anti-infective therapy Antimicrob Agents Chemother 42 1998 1529 1536
52. N. Balaban, A. Giacometti, O. Cirioni, Y. Gov, R. Ghiselli, and F. Mocchegiani Use of the quorum-sensing inhibitor RNAIII-inhibiting peptide to prevent biofilm formation in vivo by drug-resistant Staphylococcus aureus J Infect Dis 187 2003 625 630
53. D.T. Moir, K.J. Shaw, R.S. Hare, and G.F. Vovis Genomics and antimicrobial drug discovery Antimicrob Agents Chemother 43 1999 439 446
54. D.J. Payne, W.H. Miller, V. Berry, J. Brosky, W.J. Burgess, and E. Chen Discovery of a novel and potent class of FabI-directed antibacterial agents Antimicrob Agents Chemother 46 2002 3118 3124
55. T.H. Grossman, D.J. Bartels, S. Mullin, C.H. Gross, J.D. Parsons, and Y. Liao Dual targeting of GyrB and ParE by a novel aminobenzimidazole class of antibacterial compounds Antimicrob Agents Chemother 51 2007 657 666
56. A.A. Miller, G.L. Bundy, J.E. Mott, J.E. Skepner, T.P. Boyle, and D.W. Harris Discovery and characterization of QPT-1, the progenitor of a new class of bacterial topoisomerase inhibitors Antimicrob Agents Chemother 52 2008 2806 2812
57. C.J. Hackbarth, D.Z. Chen, J.G. Lewis, K. Clark, J.B. Mangold, and J.A. Cramer N-alkyl urea hydroxamic acids as a new class of peptide deformylase inhibitors with antibacterial activity Antimicrob Agents Chemother 46 2002 2752 2764
58. R.R. Breaker RNA second messengers and riboswitches: relics from the RNA world? Microbe Magazine 5 2010 13
59. K.F. Blount, J.X. Wang, J. Lim, N. Sudarsan, and R.R. Breaker Antibacterial lysine analogs that target lysine riboswitches Nat Chem Biol 3 2007 44 49
60. L. Debarbieux, D. Leduc, D. Maura, E. Morello, A. Criscuolo, and O. Grossi Bacteriophages can treat and prevent Pseudomonas aeruginosa lung infections J Infect Dis 201 2010 1096 1104
61. V.A. Fischetti, D. Nelson, and R. Schuch Reinventing phage therapy: are the parts greater than the sum? Nat Biotechnol 24 2006 1508 1511
62. A. Daniel, C. Euler, M. Collin, P. Chahales, K.J. Gorelick, and V.A. Fischetti Synergism between a novel chimeric lysin and oxacillin protects against infection by methicillin-resistant Staphylococcus aureus Antimicrob Agents Chemother 54 2010 1603 1612